Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 49.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 620 shares of the specialty pharmaceutical company’s stock after purchasing an additional 206 shares during the period. GAMMA Investing LLC’s holdings in Jazz Pharmaceuticals were worth $76,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter worth $29,000. EverSource Wealth Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. Venturi Wealth Management LLC grew its position in Jazz Pharmaceuticals by 577.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock valued at $92,000 after acquiring an additional 704 shares in the last quarter. Versant Capital Management Inc grew its position in Jazz Pharmaceuticals by 56.7% in the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after acquiring an additional 350 shares in the last quarter. Finally, Signaturefd LLC increased its stake in Jazz Pharmaceuticals by 273.4% during the third quarter. Signaturefd LLC now owns 1,516 shares of the specialty pharmaceutical company’s stock worth $169,000 after purchasing an additional 1,110 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Activity

In related news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 8,253 shares of company stock valued at $1,001,434. Insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on JAZZ. HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Piper Sandler reiterated an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. TD Cowen cut their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $121.41 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17. The stock has a market cap of $7.34 billion, a PE ratio of 17.10, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The firm has a fifty day moving average price of $122.02 and a 200 day moving average price of $114.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.